Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04757519 · ClinicalTrials.gov registry record · NA

Enhanced DPP-GLB to Promote Weight Loss Among Nonresponders in a Community-Based Lifestyle Intervention.

A NA study of Diabetes, sponsored by Lovoria Williams.

Active
Registry status
NA
Development phase
403
Enrollment target
20
Study locations

NCT04757519: Active NA study of Diabetes, sponsored by Lovoria Williams.

NCT04757519 is a NA study of Diabetes that is active but no longer recruiting, run by Lovoria Williams. The registered enrollment target is 403 participants, below the 3,027-participant average among 338 other Diabetes trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04757519, a NA study of Diabetes, is active but no longer recruiting, sponsored by Lovoria Williams.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
403 participants
Enrollment target
20
Study locations

Study Summary

This study seeks to establish the efficacy of identifying weight loss nonresponders early in a Diabetes Prevention Program (DPP) intervention in 20 community settings (primarily churches and community centers) and providing them with individual-level, enhanced treatment through telephone contacts and access to additional resources. Additionally, potential mediators and moderators of the relationship between intervention status and weight loss response at 6 months in both nonresponders and responders will be examined and a cost-effectiveness analysis to evaluate the cost of the intervention will be conducted. This study addresses key gaps in the literature about the weight loss effects of identifying nonresponders early and characterizing individuals who need more intense personalized strategies. The investigators hypothesize that changes between baseline and 3 months will be more pronounced among the nonresponders in the intervention group compared to the nonresponders in the active control group.

Primary Outcome

Weight will be measured in pounds using a cellular scale at baseline and at 12 weeks.

Conditions Studied

Interventions

  • BEHAVIORAL DPP-GLB Standard
  • BEHAVIORAL DPP-GLB Enhanced

Study Locations (20)

Kentucky

  • First Corinthian Baptist Church - Frankfort
  • Heavenly Outpour - Frankfort
  • Consolidated Baptist Church - Lexington
  • Historic St. Paul AME Church - Lexington
  • First African Baptist Church - Lexington
  • Pilgrim Baptist Church - Lexington
  • Shiloh Baptist Church - Lexington
  • Redeemed Christian Church of God - Lexington
  • First Baptist Church Brackstown - Lexington
  • Lima Drive Seventh Day Adventist Church - Lexington
  • Kingdom Fellowship - Louisville
  • Bates Memorial Baptist Church - Louisville
  • St. Stephen Baptist Church - Louisville
  • Greater Gaililee CDC - Louisville
  • Historic Calvary MBC - Louisville
  • Spirit Filled New Life Church - Louisville
  • Forest Baptist Church - Louisville
  • Burnett Ave BC - Louisville
  • Marnel C. Moorman Family Life Center - Shelbyville
  • New Mt. Zion Baptist Church - Shelbyville

Trial Details

FieldValue
Enrollment Target 403 participants
Start Date 2021-02-18
Est. Completion 2026-06-30
Phase NA
Lovoria Williams

1 total trials

What the registry record for NCT04757519 still lists

NCT04757519 is an interventional study that assigns participants to a tested intervention. The registered 403 participants enrollment target is mid-sized for trials with a published cap, below the 3,027-participant average among 338 other Diabetes trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which DPP-GLB Standard is the first listed.

NCT04757519 names 20 study sites across 1 states, led by Kentucky.

Frequently Asked Questions

What is clinical trial NCT04757519 about?

NCT04757519 is a clinical study titled "Enhanced DPP-GLB to Promote Weight Loss Among Nonresponders in a Community-Based Lifestyle Intervention.". This study seeks to establish the efficacy of identifying weight loss nonresponders early in a Diabetes Prevention Program (DPP) intervention in 20 community settings (primarily churches and community centers) and providing them with individual-level, enhanced treatment through telephone contacts an...

What is the current status of trial NCT04757519?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 403 participants. The study started on 2021-02-18. Estimated completion is 2026-06-30.

What conditions does trial NCT04757519 study?

This clinical trial studies the following conditions: Diabetes.

What interventions are being tested in trial NCT04757519?

The interventions under investigation include: DPP-GLB Standard (BEHAVIORAL), DPP-GLB Enhanced (BEHAVIORAL).

Who is sponsoring clinical trial NCT04757519?

This trial is sponsored by Lovoria Williams, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04757519 being conducted?

This trial has 20 study locations across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04757519's enrollment target sits among peer trials

403 84th of 338 higher than 255 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05647122 · 403 participants · Phase 1

    First in Human Study of AZD9592 in Solid Tumors

  • NCT05674799 · 403 participants · NA

    NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks

  • NCT06244771 · 403 participants · Phase 1

    A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

  • NCT05049057 · 404 participants · Phase 2

    Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04757519, the US trial registry maintained by the National Library of Medicine. NCT04757519 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.